Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Vergnenègre

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Revue Des Maladies Respiratoires|February 22, 2008
[The payer, the T2A pathway, the physician, the patient: the exemple of thoracic oncology]A Vergnenègre
Revue Des Maladies Respiratoires|April 24, 2003
[Cost-effectiveness analysis: a reader's guide]A Vergnenègre
Revue Des Maladies Respiratoires|March 13, 2002
[Evaluation of respiratory intensive care units at pneumology services]A Vergnenègre
Revue Des Maladies Respiratoires|February 3, 2007
[Stage IV non-small cell lung cancer. Duration of chemotherapy for locally advanced non small cell lung cancers]A Vergnenègre
Revue Des Maladies Respiratoires|April 11, 2006
[Tools for assessing healthcare delivery]A Vergnenègre
Revue Des Maladies Respiratoires|January 27, 2004
[Clinical practice guidelines: a reader's guide]A Vergnenègre
Revue Des Maladies Respiratoires|February 20, 2013
[Supportive, palliative care in lung cancer]A Vergnenègre, G Terrier
Revue Des Maladies Respiratoires|January 29, 1999
[Methodology for assessing continuing medical education at the first united French congress of pneumology]A Vergnenègre, J P Grignet
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|January 5, 2002
Economic analyses and lung cancerA Vergnenègre, L Molinier, C Chouaïd
Anti-Cancer Drugs|July 8, 2000
The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysisL Annemans, G Giaccone, A Vergnenègre
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Revue Des Maladies Respiratoires|February 22, 2008
[The payer, the T2A pathway, the physician, the patient: the exemple of thoracic oncology]A Vergnenègre
Revue Des Maladies Respiratoires|April 24, 2003
[Cost-effectiveness analysis: a reader's guide]A Vergnenègre
Revue Des Maladies Respiratoires|March 13, 2002
[Evaluation of respiratory intensive care units at pneumology services]A Vergnenègre
Revue Des Maladies Respiratoires|February 3, 2007
[Stage IV non-small cell lung cancer. Duration of chemotherapy for locally advanced non small cell lung cancers]A Vergnenègre
Revue Des Maladies Respiratoires|April 11, 2006
[Tools for assessing healthcare delivery]A Vergnenègre
Revue Des Maladies Respiratoires|January 27, 2004
[Clinical practice guidelines: a reader's guide]A Vergnenègre
Revue Des Maladies Respiratoires|February 20, 2013
[Supportive, palliative care in lung cancer]A Vergnenègre, G Terrier
Revue Des Maladies Respiratoires|January 29, 1999
[Methodology for assessing continuing medical education at the first united French congress of pneumology]A Vergnenègre, J P Grignet
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|January 5, 2002
Economic analyses and lung cancerA Vergnenègre, L Molinier, C Chouaïd
Anti-Cancer Drugs|July 8, 2000
The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysisL Annemans, G Giaccone, A Vergnenègre
Pageof 5